Apollomics Inc. (NASDAQ:APLM – Get Free Report)’s share price was down 1.1% on Monday . The company traded as low as $13.53 and last traded at $13.75. Approximately 640 shares changed hands during trading, a decline of 93% from the average daily volume of 8,911 shares. The stock had previously closed at $13.90.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Apollomics in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Apollomics presently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on Apollomics
Apollomics Stock Down 1.1%
Institutional Trading of Apollomics
An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent SEC filing. Institutional investors and hedge funds own 19.13% of the company’s stock.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
See Also
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
